Japan

Jascayd acts as the first phosphodiesterase 4B (PDE4B) inhibitor approved for these indications, offering both antifibrotic and immunomodulatory activity.

The treatment is approved in the United States for adults and pediatric patients aged six months and older, making it one of the few targeted therapies available for this condition.

The robot-assisted technologies under this agreement respond directly to this challenge by improving clinical outcomes and reducing procedural complications.

By integrating Aicuris into its global development and commercialization infrastructure, Asahi Kasei accelerates its expansion in the specialty pharmaceutical sector.

For Daiichi Sankyo, divesting this business allows the company to concentrate resources on its innovative medicines division, where it has emerged as a leader in antibody-drug conjugate (ADC) technology.

In Japan alone, 21,000 new cases and 7,000 deaths were reported that year, with metastatic renal cell carcinoma (RCC) accounting for approximately 85% of all kidney cancers.

This latest commitment builds on a previous 7 billion yen (USD44 million) investment between 2022 and 2025, which funded automated device-sorting machines, enhancements to the quality testing lab, a new factory building, and an additional packaging line.

The hospital processes approximately 16,000 discharge summaries each year, making this a significant opportunity for efficiency gains.

The partnership merges Fujitsu Japan’s deep knowledge of the medical field and cutting-edge technologies, including artificial intelligence, with JMDC’s sophisticated prediction models derived from insurance user data.

Hetronifly is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody that has already received regulatory approval in China for treating several solid tumor types.